Organisation paid for research Program year 2025 Source: CMS Open Payments

Hightower Clinical

Neither a doctor nor a teaching hospital

Research payments

$839,572

139 payments

Through program year 2025, Hightower Clinical is reported as receiving $839,572 in research payments, across 139 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$87,124	28
2024	Research	$218,358	40
2023	Research	$182,887	18
2022	Research	$179,368	28
2021	Research	$169,314	24
2020	Research	$2,521	1

Breakdown

Who paid Research payments · program years 2020–2025

Abbott Laboratories $433,956 92 payments
Amgen Inc. $163,950 9 payments
Pfizer Inc. $148,274 28 payments
Biohaven Pharmaceuticals, Inc. $52,570 6 payments
Celgene Corporation $40,500 3 payments
AbbVie, Inc. $322 1 payment

Studies the money was for Research payments · program years 2020–2025

Aveir Dual-Chamber Leadless i2i IDE Study $124,773 6 payments
Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis $112,514 25 payments
Ph4 PMR Avacopan in subjects with ANCA-associated vasculitis CL018_168 $88,435 2 payments
Amplatzer Amulet LAAO vs. NOAC (CATALYST) $56,233 4 payments
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $50,049 5 payments
NCT06656364--Esprit BTK Post-Approval Study $36,557 9 payments
A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 VS Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 $35,760 3 payments
CATALYST IDE Study $33,996 5 payments
VOLT-AF IDE Clinical Study $27,641 6 payments
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies $27,307 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.